PharmaEssentia Corporation

Equities

6446

TW0006446008

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 23:00:00 21/05/2024 BST			5-day change	1st Jan Change
406.5 ^TWD	-5.47%		+15.16%	+17.49%

05-13	PharmaEssentia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-26	PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	CI

PharmaEssentia Corporation Announces Appointment of Lih-Ling Lin as Chief Scientific Officer

August 01, 2022 at 11:07 am

PharmaEssentia Corporation announced appointment of Lih-Ling Lin as Chief Scientific Officer, effective from August 1, 2022. Name, title, and resume of the new position holder: Lih-Ling Lin /Chief Scientific Officer /The Head of Checkpoint immunology cluster in Immunology and Inflammation Research Area at Sanofi.

Latest news about PharmaEssentia Corporation

PharmaEssentia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	04-26	CI
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia	04-24	CI
PharmaEssentia Corporation cancelled the transaction announced on April 2, 2024	04-15	CI
PharmaEssentia Corporation announced a financing transaction	04-01	CI
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon Alfa-2b) for PV in Brazil	03-28	CI
PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA	03-04	CI
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration	03-04	CI
PharmaEssentia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
PharmaEssentia Corporation(TWSE:6446) added to Taiwan TAIEX Index	02-18	CI
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer	01-24	MT
PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA	01-17	CI
PharmaEssentia Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia	25/10/23	CI
Pharmaessentia Corporation Enters into Exclusive Global License Agreement with Wuxi Biologics for A Myeloid Immune Checkpoint Antibody Candidate	03/10/23	CI
Tranche Update on PharmaEssentia Corporation's Equity Buyback Plan announced on July 28, 2023.	28/09/23	CI
PharmaEssentia Corporation's Equity Buyback announced on July 28, 2023, has closed with 4,000,000 shares, representing 1.19% for TWD 1,351.42 million	27/09/23	CI
Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B for the Treatment of PV in China	20/09/23	CI
PharmaEssentia Corporation(TPEX:6446) added to FTSE All-World Index	18/09/23	CI
PharmaEssentia Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
PharmaEssentia Corporation announces an Equity Buyback for 4,000,000 shares, for TWD 8,846.64 million.	28/07/23	CI
PharmaEssentia Corporation authorizes a Buyback Plan.	27/07/23	CI
Tranche Update on PharmaEssentia Corporation's Equity Buyback Plan announced on May 24, 2023.	21/07/23	CI
PharmaEssentia Corporation's Equity Buyback announced on May 24, 2023, has expired with 4,001,000 shares, representing 1.31% for TWD 1,366.17 million.	20/07/23	CI
Certain Common Shares of PharmaEssentia Corporation are subject to a Lock-Up Agreement Ending on 18-JUL-2023.	17/07/23	CI

Chart PharmaEssentia Corporation

Duration

Period

More charts

Company Profile

PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Companyâs products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

27/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for PharmaEssentia Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

406.5 TWD

Average target price

428.2 TWD

Spread / Average Target

+5.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHARMAESSENTIA CORPORATION	+17.49%	4.18B
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	115B
REGENERON PHARMACEUTICALS, INC.	+12.01%	106B
BIONTECH SE	-3.07%	24.69B
ARGENX SE	-0.70%	21.97B
GENMAB A/S	-4.69%	19.27B
BEIGENE, LTD.	-6.90%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.13B

Bio Therapeutic Drugs